X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA FRESENIUS KABI ONCO. PLETHICO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -1.1 22.1 - View Chart
P/BV x 0.0 3.1 0.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
PLETHICO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs395176 224.4%   
Low Rs3179 39.9%   
Sales per share (Unadj.) Rs604.437.7 1,603.8%  
Earnings per share (Unadj.) Rs32.55.1 637.7%  
Cash flow per share (Unadj.) Rs51.36.7 763.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.642.5 1,113.1%  
Shares outstanding (eoy) m34.08158.23 21.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.4 10.4%   
Avg P/E ratio x6.625.0 26.3%  
P/CF ratio (eoy) x4.218.9 21.9%  
Price / Book Value ratio x0.53.0 15.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,26220,135 36.1%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m1,596703 227.0%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m20,5985,963 345.4%  
Other income Rs m38618 2,146.3%   
Total revenues Rs m20,9845,981 350.8%   
Gross profit Rs m2,8181,430 197.0%  
Depreciation Rs m642258 249.1%   
Interest Rs m1,593-26 -6,127.7%   
Profit before tax Rs m9691,216 79.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m-138342 -40.4%   
Profit after tax Rs m1,107806 137.3%  
Gross profit margin %13.724.0 57.0%  
Effective tax rate %-14.328.1 -50.8%   
Net profit margin %5.413.5 39.8%  
BALANCE SHEET DATA
Current assets Rs m18,8775,102 370.0%   
Current liabilities Rs m11,8962,385 498.7%   
Net working cap to sales %33.945.6 74.4%  
Current ratio x1.62.1 74.2%  
Inventory Days Days36150 24.0%  
Debtors Days Days198113 174.6%  
Net fixed assets Rs m9,8615,148 191.5%   
Share capital Rs m341158 215.4%   
"Free" reserves Rs m12,3316,556 188.1%   
Net worth Rs m16,1396,732 239.7%   
Long term debt Rs m4,706952 494.2%   
Total assets Rs m33,14610,388 319.1%  
Interest coverage x1.6-45.8 -3.5%   
Debt to equity ratio x0.30.1 206.1%  
Sales to assets ratio x0.60.6 108.3%   
Return on assets %8.17.5 108.5%  
Return on equity %6.912.0 57.3%  
Return on capital %12.314.6 84.2%  
Exports to sales %21.474.5 28.7%   
Imports to sales %15.224.8 61.4%   
Exports (fob) Rs m4,4024,441 99.1%   
Imports (cif) Rs m3,1361,477 212.3%   
Fx inflow Rs m4,4025,298 83.1%   
Fx outflow Rs m3,1841,772 179.7%   
Net fx Rs m1,2193,525 34.6%   
CASH FLOW
From Operations Rs m2,4371,274 191.3%  
From Investments Rs m-6,265-1,204 520.2%  
From Financial Activity Rs m2,490-196 -1,269.8%  
Net Cashflow Rs m-1,337-126 1,058.7%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 4.3 0.3 1,433.3%  
FIIs % 5.5 9.6 57.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 9.1 82.4%  
Shareholders   10,665 42,599 25.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DR. DATSONS LABS  BIOCON LTD  FULFORD INDIA  JUBILANT LIFE SCIENCES  AJANTA PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Power Stocks Top Losers(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS